Cargando…

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit aberrantly activated pathways and/or to unleash...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonarelli, Gabriele, Giugliano, Federica, Corti, Chiara, Repetto, Matteo, Tarantino, Paolo, Curigliano, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468026/ https://www.ncbi.nlm.nih.gov/pubmed/34577584 http://dx.doi.org/10.3390/ph14090884

Ejemplares similares

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
por: Belli, Carmen, et al.
Publicado: (2022)

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023)

Bispecific Antibodies in the Treatment of Hematologic Malignancies
por: Duell, Johannes, et al.
Publicado: (2019)

Bispecific Antibodies Progression in Malignant Melanoma
por: Tang, Juan, et al.
Publicado: (2022)

Recent advances of bispecific antibodies in solid tumors
por: Yu, Shengnan, et al.
Publicado: (2017)

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials
por: Trillo Aliaga, Pamela, et al.
Publicado: (2021)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Bispecific Antibodies: From Research to Clinical Application
por: Ma, Jiabing, et al.
Publicado: (2021)

Recent advances and challenges of bispecific antibodies in solid tumors
por: Wu, Yuze, et al.
Publicado: (2021)

Therapeutic cancer vaccines revamping: technology advancements and pitfalls
por: Antonarelli, G., et al.
Publicado: (2021)

Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022)

The Current Landscape of Antibody-based Therapies in Solid Malignancies
por: Shah, Ashu, et al.
Publicado: (2021)

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies
por: Lejeune, Margaux, et al.
Publicado: (2020)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Bispecific Antibodies in Hematological Malignancies: A Scoping Review
por: Omer, Mohamed H., et al.
Publicado: (2023)

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
por: Liguori, Luigi, et al.
Publicado: (2022)

Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2023)

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)

Immunotherapy for early triple negative breast cancer: research agenda for the next decade
por: Tarantino, Paolo, et al.
Publicado: (2022)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

1583P COVID-19 related risk in patients enrolled in early-phase clinical trials
por: D'Amico, P., et al.
Publicado: (2021)

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
por: Middelburg, Jim, et al.
Publicado: (2021)

T‐cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions
por: O'Neill, Chloe, et al.
Publicado: (2023)

SARS-CoV-2 vaccines for cancer patients: a call to action
por: Corti, Chiara, et al.
Publicado: (2021)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Bispecific antibodies and their applications
por: Fan, Gaowei, et al.
Publicado: (2015)

The making of bispecific antibodies
por: Brinkmann, Ulrich, et al.
Publicado: (2017)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

A NOVEL MSLN×4-1BB BISPECIFIC ANTIBODY FOR SOLID TUMOR
por: Cheng, Liansheng, et al.
Publicado: (2023)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
por: Valenza, Carmine, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
por: Yoon, Aerin, et al.
Publicado: (2020)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Design and Production of Bispecific Antibodies
por: Wang, Qiong, et al.
Publicado: (2019)

Bispecific Antibodies for Diagnostic Applications
por: Parashar, Archana, et al.
Publicado: (2011)

Bispecific Antibodies and Gene Therapy
por: Nettelbeck, Dirk M.
Publicado: (2011)

Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review
por: Nejadghaderi, Seyed Aria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gdee7jldlte1sj0s2639qt7g1e